Have a feature idea you'd love to see implemented?
Let us know!
UBX Unity Biotechnology Inc
Price (delayed)
$1.48
Market cap
$24.93M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.74
Enterprise value
$39.01M
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells
Highlights
UBX's debt is down by 50% year-on-year and by 4.2% since the previous quarter
The EPS is up by 30% since the previous quarter
The quick ratio has grown by 24% YoY but it has contracted by 18% from the previous quarter
UBX's equity has dropped by 60% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of UBX
Market
Valuations
Earnings
Shares outstanding
16.85M
Market cap
$24.93M
Enterprise value
$39.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$27.39M
EBITDA
-$26.4M
Free cash flow
-$24.33M
Per share
Balance sheet
Liquidity
EPS
-$1.74
Free cash flow per share
-$1.45
Book value per share
$1.18
Revenue per share
$0
TBVPS
$3.18
Total assets
$53.52M
Total liabilities
$33.77M
Debt
$21.66M
Equity
$19.75M
Working capital
$27.03M
Debt to equity
1.1
Current ratio
4.07
Quick ratio
3.85
Net debt/EBITDA
-0.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45%
Return on equity
-102.8%
Return on invested capital
-41.5%
Return on capital employed
-61.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UBX stock price
How has the Unity Biotechnology stock price performed over time
Intraday
-0.67%
1 week
3.5%
1 month
2.78%
1 year
-19.13%
YTD
-23.32%
QTD
0.68%
Financial performance
How have Unity Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$36.63M
Net income
-$27.86M
Gross margin
N/A
Net margin
N/A
UBX's net income is up by 27% from the previous quarter and by 16% YoY
UBX's operating income is up by 26% year-on-year and by 12% since the previous quarter
Growth
What is Unity Biotechnology's growth rate over time
Valuation
What is Unity Biotechnology stock price valuation
P/E
N/A
P/B
1.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 30% since the previous quarter
UBX's equity has dropped by 60% year-on-year and by 18% since the previous quarter
The P/B is 34% less than the 5-year quarterly average of 1.9 but 26% more than the last 4 quarters average of 1.0
Efficiency
How efficient is Unity Biotechnology business performance
UBX's return on equity has dropped by 88% year-on-year but it is up by 7% since the previous quarter
UBX's ROIC has dropped by 77% year-on-year but it is up by 13% since the previous quarter
UBX's ROA has dropped by 61% year-on-year but it is up by 13% since the previous quarter
Dividends
What is UBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UBX.
Financial health
How did Unity Biotechnology financials performed over time
UBX's total assets is 58% greater than its total liabilities
UBX's total assets is down by 47% year-on-year and by 9% since the previous quarter
Unity Biotechnology's total liabilities has decreased by 35% YoY and by 3.2% QoQ
UBX's debt is 10% greater than its equity
UBX's equity has dropped by 60% year-on-year and by 18% since the previous quarter
UBX's debt is down by 50% year-on-year and by 4.2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.